SOX2 and lung carcinoma: Furthermore, SOX2‐OT has been proposed as a ncRNA biomarker for diagnostic and prognostic purposes in patients with malignant lung diseases [25, 26], highlighting that SOX2‐OT is associated with poor patient survival, probably by promoting epigenetic aberrations in lung cancer [22].